Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer

Trial Profile

Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Depoxythilone (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Beijing Biostar Technologies
  • Most Recent Events

    • 10 Feb 2017 Results published in the Lancet Oncology
    • 07 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Primary endpoint (Progresssion free survival (PFS)) has been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top